Irish pharmaceutical firm Amarin has reported positive results from its first phase three clinical trial of its AMR101 heart drug.
The trials found that the use of the treatment resulted in a significant reduction in triglycerides in patients. Triglycerides are the chemical form of fat in the body, and high levels have been linked to an increased risk of heart disease.
Amarin said that, as a result of the trials, it would now submit a new drug application for AMR101 to the US authorities next year. This would give the company permission to market and sell the treatment in the US. It is also ahead of a previous target of 2012 for the application.